Q3 2021 13F Holders as of 9/30/2021
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
44.2M
-
Number of holders
-
59
-
Total 13F shares, excl. options
-
35.9M
-
Shares change
-
+1.48M
-
Total reported value, excl. options
-
$1.12B
-
Value change
-
+$46.3M
-
Number of buys
-
33
-
Number of sells
-
-18
-
Price
-
$31.25
Significant Holders of Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (PRLD) as of Q3 2021
64 filings reported holding PRLD - Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share as of Q3 2021.
Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (PRLD) has 59 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 35.9M shares
of 44.2M outstanding shares and own 81.36% of the company stock.
Largest 10 shareholders include BAKER BROS. ADVISORS LP (10.1M shares), ORBIMED ADVISORS LLC (10M shares), FMR LLC (7.06M shares), UBS ASSET MANAGEMENT AMERICAS INC (1.48M shares), VANGUARD GROUP INC (1.14M shares), STATE STREET CORP (850K shares), MORGAN STANLEY (757K shares), BlackRock Inc. (726K shares), HHLR ADVISORS, LTD. (583K shares), and MASSACHUSETTS FINANCIAL SERVICES CO /MA/ (472K shares).
This table shows the top 59 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.